Zymeworks Inc. (ZYME)
PHARMACEUTICAL PREPARATIONS
Zymeworks Inc. (ZYME) is listed on Nasdaq, where it has traded since April 28, 2017.
- Listed On
- Nasdaq
- Listed Since
- April 28, 2017
- Employees
- 264
- Market Cap
- $2.1B
About Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 194 institutions reported holding ZYME, with 68.1 million shares worth $1.8 billion in aggregate. The largest reported holder was Ecor1 Capital, with 23.0 million shares worth $600.4 million. Of the 5 largest holders listed below, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Ecor1 Capital | 22,970,388 | $600M | Unchanged |
| Rubric Capital Management | 7,000,000 | $183M | Unchanged |
| BlackRock | 4,251,030 | $111M | Reduced 6.65% |
| Perceptive Advisors | 4,182,953 | $109M | Added 19.17% |
| Bvf Inc/IL | 3,649,142 | $95M | Reduced 2.28% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ZYME?
Zymeworks Inc. (ZYME) is listed on Nasdaq, where it has traded since April 28, 2017.
Who are the largest institutional holders of ZYME?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ZYME were Ecor1 Capital, Rubric Capital Management and BlackRock.
How many institutions own ZYME?
194 institutions reported a position in ZYME for the quarter ended June 30, 2026, worth $1.8 billion in total.
Did institutions buy or sell ZYME last quarter?
Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ZYME.
Every reported institutional holder, plus insider and congressional trades in ZYME, on SentiSense.